CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR (CBRN) MEDICAL COUNTERMEASURES

Investments support advanced research & development and procurement of CBRN medical countermeasures (MCMs) to address national security threats.

BARDA Programs

CBRN MCM DASHBOARD

box
20
CBRN MCM National Security Procurements
euas
$1.5B
Invested in CBRN MCM
in FY2020
Last Updated 6/08/2021

CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR PROGRAMS

BARDA is the lead office within HHS for the advanced research & development (AR&D) as well as procurement of medical countermeasures (MCMs) to protect the American civilian population from CBRN threats. Ultimately, these MCMs are used to help the Nation prepare for, respond to, and recover from public health emergencies arising from naturally occurring and intentionally engineered threats. CBRN uses its AR&D authorities to help innovators develop promising candidate MCMs from preclinical development to clinical trials and manufacturing scale-up to FDA approval. CBRN leverages its Project BioShield (PBS) authorities to procure approved or approvable MCMs to save lives and protect Americans from 21st century health security threats.

CBRN'S GOALS

Make Available at Least One Countermeasure for all CBRN Material Threats

CBRN Goals: invest in MCMs to treat injury not threat, innovative MCMs for unknown threats, and deliver novel MCMs for bacterial and viral threats
Hear directly from the BARDA CBRN director on his 2021 priorities.
BARDA Industry Day 2020
Dr. Chris Houchens, BARDA CBRN Division Director
Pre-recorded for October 17, 2020

Funding Opportunities based on the Product Stage

Advanced Research and Development (A&RD)

The goal of AR&D funding is to build a sustainable MCM pipeline to prevent or treat illnesses and injuries caused by CBRN threats. AR&D funds support innovative products through all phases of the development pipeline, from discovery and preclinical research, to clinical trials needed to prove safety and efficacy, and manufacturing and regulatory approval needed to bring a product to market. CBRN also uses AR&D funding to develop and utilize preclinical models to study the illnesses and injuries caused by CBRN threats and the MCMs to treat those illnesses and injuries.


BARDA is investing in an array of medical countermeasures to treat or prevent illnesses and injuries caused by CBRN threats under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003).
Learn More or Apply >
Project BioShield (PBS)

BARDA uses Project BioShield funding to support late-stage development, including post-marketing requirements and Phase IV clinical trials, and procurement of critical medical countermeasures, including vaccines and therapeutics, to prevent and treat CBRN threats. These MCMs are made available when a public health emergency, such as an anthrax attack or a nuclear detonation, occurs.


Check back soon for links to Requests for Proposals (RFP) for new efforts to be supported by Project BioShield funds.
Explore our CBRN Portfolio >
First ReDIRECT New Partnership Announced

Learn how DRIVe and CBRN are collaborating to form new partnerships under the new ReDIRECT program to repurpose drugs approved for other indications to treat injuries caused by chemical threats.

CBRN Strategic Priorities

CBRN invests in innovative MCMs to treat or prevent the medical consequences that result from naturally occurring and intentionally engineered chemical, biological, radiological, and nuclear threats.

BARDA’s Expanding
CBRN Medical Countermeasure Portfolio

CBRN has a proven track record of developing life-saving medical countermeasures. We will continue to work with partners old and new to treat or prevent the medical consequences that result from CBRN threats.

LEARN MORE ABOUT CBRN'S MCM INNOVATION PROGRAMS

CBRN REPORTS AND REFERENCES

Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov